Research Article | Open Access
SIRT1/3 Activation by Resveratrol Attenuates Acute Kidney Injury in a Septic Rat Model
Sepsis often results in damage to multiple organ systems, possibly due to severe mitochondrial dysfunction. Two members of the sirtuin family, SIRT1 and SIRT3, have been implicated in the reversal of mitochondrial damage. The aim of this study was to determine the role of SIRT1/3 in acute kidney injury (AKI) following sepsis in a septic rat model. After drug pretreatment and cecal ligation and puncture (CLP) model reproduction in the rats, we performed survival time evaluation and kidney tissue extraction and renal tubular epithelial cell (RTEC) isolation. We observed reduced SIRT1/3 activity, elevated acetylated SOD2 (ac-SOD2) levels and oxidative stress, and damaged mitochondria in RTECs following sepsis. Treatment with resveratrol (RSV), a chemical SIRT1 activator, effectively restored SIRT1/3 activity, reduced acetylated SOD2 levels, ameliorated oxidative stress and mitochondrial function of RTECs, and prolonged survival time. However, the beneficial effects of RSV were greatly abrogated by Ex527, a selective inhibitor of SIRT1. These results suggest a therapeutic role for SIRT1 in the reversal of AKI in septic rat, which may rely on SIRT3-mediated deacetylation of SOD2. SIRT1/3 activation could therefore be a promising therapeutic strategy to treat sepsis-associated AKI.
Sepsis is a frequently fatal condition characterized by uncontrolled and adverse host reactions to microbial infection , accounting for more than $20 billion (5.2%) of total US hospital costs in 2011 . Sepsis is, by conservative estimates, a leading cause of mortality and critical illness worldwide [3, 4]; however, its pathophysiology remains unclear. The current consensus is that the development of sepsis is characterized by multiple organ dysfunction . The kidney is frequently affected during sepsis, and acute kidney injury (AKI) is a common occurrence during the pathogenesis of sepsis . Tubular cells exhibit reduced oxygen consumption in response to sepsis, indicating severe mitochondrial dysfunction (MD) . Furthermore, our previous studies have shown that severe MD in renal tubular epithelial cells accelerates AKI in a rat model of sepsis .
There is increasing evidence that silent mating type information regulation 2 homolog 1 (sirtuin 1, SIRT1) plays an important role in mitochondrial protection. Through deacetylation of histone and nonhistone substrate, SIRT1 is involved in various metabolic and inflammatory diseases [8, 9]. Interestingly, SIRT1 activity is decreased in the liver, spleen, small bowel, and lung tissue in experimental sepsis models, and SIRT1 activation could improve the outcome of sepsis and ameliorate the associated inflammatory response [10, 11]. Besides SIRT1, another sirtuin, SIRT3, has also received considerable attention [12, 13]. Several reports indicate that SIRT3 is exclusively located in the mitochondria and acts as an antioxidative enzyme . In a previous study, our group found that activation of SIRT1/3 improves vascular hyporeactivity in severe hemorrhagic shock by alleviation of mitochondrial damage . However, the role of SIRT1/3 on mitochondrial protection following sepsis is not reported. In this study, we used a septic rat model to determine the effects of SIRT1 and SIRT3 on acute kidney injury (AKI) following sepsis.
2. Materials and Methods
2.1. Reagents and Antibodies
SOD2 Activity kit was purchased from Dojindo (Kumamoto, Japan). Antibodies against SOD2 and acetylated superoxide dismutase 2 (ac-SOD2) as well as SIRT1 and SIRT3 Deacetylase Fluorometric Assay kits were obtained from Cyclex (Nagano, Japan). Antibody against SIRT1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody against SIRT3 was purchased from ABClonal (Boston, MA, USA). Antibodies against acetylated lysine and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from CST (Danvers, MA, USA). Immunoprecipitation kits were obtained from Proteintech (Chicago, IL, USA). Membrane-permeant JC-1 dye and calcein-AM were purchased from Molecular Probes (Eugene, OR, USA). Assay kits for reduced glutathione/oxidized glutathione (GSH/GSSG) and catalase (CAT) were obtained from Beyotime Biotech (Beijing, China). A CellTiter-Glo® Assay kit and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining kit were purchased from Promega (Madison, WI, USA). Polyvinylidene fluoride (PVDF) membranes were obtained from Millipore (Billerica, MA, USA). 3-(1H-1,2,3-Triazol-4-yl)pyridine (3-TYP), a selective inhibitor of SIRT3, was synthesized and characterized by the School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China, based on our previous work . All other chemicals were purchased from Sigma-Aldrich (Saint Louis, MO, USA).
2.2. CLP Model of Sepsis
The present study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health, Bethesda, MD, USA). The study protocol was approved by the Committee on Ethics in Animal Experiments of Southern Medical University.
In total, 64 specific pathogen-free Sprague-Dawley rats (male or female) weighing 180–220 g were used in this study. The rats were housed in plastic cages with a controlled temperature of 25°C, humidity of 50–55%, and a 12 h light/dark cycle. All the animals had free access to food and distilled water. All rats were anesthetized and maintained with isoflurane (RWD Life Science, Shenzhen, China) and were randomly divided into six groups: the control, vehicle, resveratrol (RSV), SRT1720 (a selective activator of SIRT1), RSV+Ex527, and RSV+3-TYP groups.(1)In the control group, rats were anesthetized and underwent surgery without any other treatment.(2)In the vehicle group, the rats were given vehicle (0.3 mL) and subjected to cecal ligation and puncture (CLP) after 30 min.(3)In the RSV group, the rats were given RSV (0.3 mL; 50 mg/kg) and subjected to CLP after 30 min.(4)In the SRT1720 group, the rats were given SRT1720 (0.3 mL; 0.2 mg/kg)  and subjected to CLP after 30 min.(5)In the RSV+Ex527 group, rats were given RSV+Ex527 (0.3 mL, 50 mg/kg, and 5 mg/kg, resp.) and subjected to CLP after 30 min.(6)In the RSV+3-TYP group, the rats were given RSV+3-TYP (0.3 mL, 50 mg/kg, and 5 mg/kg, resp.)  and subjected to CLP after 30 min.
Sepsis was introduced by using the CLP technique. Specifically, midline laparotomy was performed using minimal dissection, and the cecum was ligated just below the ileocecal valve by using 4-0 silk ligatures to maintain intestinal continuity. The cecum was perforated at 2 locations 1 cm apart by using an 18-gauge needle and gently compressed until the feces were extruded. The bowel was then returned to the abdomen and the incision closed. Control rats underwent the same surgical procedures, but the cecum was neither ligated nor punctured. At the end of the operation, all rats were subcutaneously resuscitated with vehicle (normal saline, NS; 20 mL/kg). All rats were deprived of food but had free access to water after the operation. All rats received subcutaneous injections of imipenem/cilastatin (14 mg/kg) in 8 mL NS solution (40 mL/kg) at 6 h after CLP.
After the CLP model was created, 36 rats (6 in each group) were killed for tissue extraction, observation of mitochondrial morphology, and renal tubular epithelial cell (RTEC) isolation; the remaining animals (8 in each group) were used for survival analyses.
2.3. RTEC Isolation
A portion of extracted renal tissue from each group was used for isolation of RTECs by our previously described methods . Briefly, the cortex was cut into fragments, and cells were dissociated by incubation with 1 mg/mL type-I collagenase for 30 min at 37°C. Red blood cells were removed by lysis. RTECs were separated by Percoll gradient density centrifugation. The purity of the RTECs was determined by immunostaining with cytokeratin-18 and Hoechst dye.
2.4. Western Blotting
Both kidney tissue and isolated RTECs were centrifuged at 14000 rpm for 10 minutes after homogenization in Radio-Immunoprecipitation Assay (RIPA) lysis buffer, and the clear supernatants were collected. Total protein concentrations in the supernatants were determined by the bicinchoninic acid (BCA) method. Then, the protein was boiled at 98°C for 5 to 10 minutes and stored at −80°C for later analysis. Equal amounts of protein samples were electrophoresed through a 7.5% SDS-polyacrylamide gel and then transferred onto polyvinylidene difluoride (PVDF) membrane using wet transfer at 100 V for 90 minutes at 4°C. Nonspecific binding sites were blocked by 1% BSA in 0.05% Tween-20 Tris-buffered saline (TBST) and then incubated overnight at 4°C with primary antibodies. After incubation with primary antibodies (against SIRT1, SIRT3, SOD2, cytochrome C, and GAPDH) and secondary antibodies, protein bands were detected using chemiluminescence detection reagents. GAPDH was used as an internal reference. Ac-SOD2 levels on immunoprecipitated SOD2 protein were measured. Band intensity was quantified by scanning densitometry. Each measurement was made at least 3 times.
2.5. SIRT1/3 Activity
Activity of SIRT1 deacetylase was detected using SIRT1 (Cyclex, Cat#CY-1151V2) and SIRT3 Deacetylase Fluorometric Assay kits (Cyclex, Cat#CY-1153V2) as described previously . Briefly, renal tissue samples (50 mg) or RTECs were homogenized in 500 μL immunoprecipitation buffer. After immunoprecipitation of SIRT1/3, final reaction mixtures (50 μL) contained 50 mM Tris-HCl (pH 8.8), 4 mM MgCl2, 0.5 mM dithiothreitol, 0.25 mA/mL lysyl endopeptidase, 1 μM trichostatin A, 200 μM NAD+, and 5 μL extraction buffer. Fluorescence intensity at 350 nm/450 nm was measured using an Automatic Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). Activity was presented as a relative value compared with that of the control group.
2.6. SOD2 Activity
SOD2 activity was measured with a commercially available kit using water-soluble tetrazolium salt- (WST-) 1 as a substrate . Briefly, total SOD activity of each immunoprecipitated protein (normalized to that of the control group) was measured by inhibition of the rate of WST-1 reduction. Potassium cyanide was added to the lysate during the assay to inhibit both SOD1 and SOD3. Absorbance was read at 450 nm using a Microplate Reader (SpectraMax M5). Relative SOD2 activity (compared with that of the control group) is shown.
2.7. GSH Content, GSH/GSSG Ratio, and CAT Activity
GSH, the GSSG/GSH ratio, and CAT activity in isolated RTECs were evaluated using kits according to manufacturer instructions and standard methods. Briefly, 200 μL of homogenized cell samples was mixed with the reagent provided in the kit and was processed in boiled water and then ice as stated in the instruction. Absorbance at 520 nm was obtained for GSH and GSSG by a Microplate Reader, and the concentrations of these two enzymes were calculated. For CAT, absorbance at 520 nm was obtained on a UV spectrophotometer. The relative values of CAT compared to the control group were then calculated.
2.8. Mitochondrial Morphology
All rats (6 in each group) were killed and the renal tissue was used for morphological observation and protein extraction. Morphological changes in the mitochondria of cells from renal tissue were observed using transmission electron microscopy. Renal tissues were fixed with 2.5% glutaraldehyde and stained with cacodylate-buffered osmium tetroxide. Sections were prepared and examined under an electron microscope (H-7500; Hitachi, Tokyo, Japan) .
2.9. Evaluation of Mitochondrial Function
Isolated cells were used for the detection of mitochondrial function (mitochondrial membrane potential (), cellular level of adenosine triphosphate (ATP), and mitochondrial permeability transition pore (mPTP)), as described previously. Mitochondrial function-related indices such as the (using membrane-permeant JC-1 dye) and mPTP were analyzed using a Flow Cytometer (FACSVerse; Becton Dickinson, San Jose, CA, USA). The aggregates-to-monomers ratio of JC-1 represented the . Fluorescence intensity reflected the status of opening of the mPTP. ATP content was measured by an assay that measures ATP through the energy-dependent luciferase/luciferin reaction and provides information on cell viability. The test was performed according to manufacturer instructions. After counting cells, 100 μL CellTiter-Glo was added to a cell suspension (100 μL) containing 10,000 isolated cells in each well of a standard opaque-walled 96-well plate. Plates were incubated at room temperature for 10 min, and luminescence was recorded in a SpectraMax M5 Microplate Reader (Molecular Devices, Sunnyvale, CA) .
2.10. TUNEL Apoptosis Assay
For detection of apoptotic cells, TUNEL staining was carried out using a Promega apoptosis detection kit. Immunofluorescence for TUNEL staining was performed with fluorescein isothiocyanate (FITC). The glass was mounted with cover slips containing 4′,6-diamidino-2-phenylindole (DAPI) and imaged under a Confocal Microscope (LSM 780; Carl Zeiss, Oberkochen, Germany). Cells stained green fluorescence and DAPI stained blue fluorescence were detected as TUNEL-positive apoptotic cells. Both TUNEL-positive and DAPI-positive cells were counted in 10 random high-power fields (HPF; 300-cells each). Data are expressed as the number of apoptotic cells/HPF (400x magnification).
2.11. Animal Survival
Some of the animals in each group (32 rats in total, 8 in each group) were assigned to a subgroup for survival analyses. To minimize suffering, pentobarbital sodium (30 mg/kg, i.p.) was given intermittently to conscious animals. Animals had access to food and water ad libitum. Apnea for >1 min was considered to indicate death. At the end of CLP, catheters were removed and skin wounds were sutured. Survival time and the prevalence of survival at 48 h were recorded. Rats that survived for >7 d were killed by cervical dislocation.
2.12. Statistical Analyses
Median survival was analyzed using Kaplan–Meier plots and compared using the log-rank test. Other data were presented as the mean ± standard deviation and were analyzed using SPSS 20.0 (IBM, Armonk, NY, USA). Levene’s test was used to ascertain if groups had equal variance. Moreover, one-way analysis of variance (ANOVA) followed by Tukey’s test was applied. If equal variances were not assumed (based on Levene’s test; ), Dunnett’s T3 post hoc comparisons were used for robust tests of equality of mean values. Level of significance was set at .
3.1. SIRT1 Activity Was Decreased in Renal Tissue following CLP
To determine whether SIRT1 is involved in the pathogenesis of sepsis-induced AKI, we studied both the activity and protein expression of SIRT1 in renal tissue (Figure 1). The rats were killed 4, 8, 16, and 24 h after CLP treatment and AKI was confirmed as previously described . As expected, SIRT1 protein expression and activity, particularly SIRT1 activity, progressively reduced 8 h after CLP. After that, both protein expression and activity were partially restored. Therefore, 8 h after CLP treatment was selected as the time point in the follow-up study.
3.2. SIRT1 Activity Was Decreased in RTECs following CLP
We then explored which kind of renal cell contributed to the decreased SIRT1 activity. Both the RTECs and glomerular cells were isolated immediately after the rats were executed. To further test the role of SIRT1 in AKI induced by CLP, the SIRT1 chemical activator RSV and SRT1720 and inhibitor Ex527 were used. SIRT1 protein expression and activity were considerably reduced in RTECs compared to that in glomerular cells (see Supplementary Figure in Supplementary Material available online at http://dx.doi.org/10.1155/2016/7296092).
Furthermore, RSV greatly restored SIRT1 activity and slightly elevated the SIRT1 protein expression. Interestingly, SRT1720 addition increased the SIRT1 activity slightly more than RSV treatment alone. In contrast, the beneficial effect of RSV was blocked after Ex527 was added (Figure 2).
3.3. SIRT3 Activity Was Reduced in RTECs following CLP
Based on the importance of the SIRT1/3 axis in the pathogenesis of severe shock , we hypothesized that SIRT3 may play a role in sepsis. SIRT3 expression and activity in RTECs were tested. Consistent with our observations regarding SIRT1, the SIRT3 expression and activity were reduced following CLP and were restored by RSV treatment; however, the beneficial effect of RSV on SIRT3 was either abrogated by Ex527 (a selective inhibitor of SIRT1) or 3-TYP (a selective inhibitor of SIRT3) (Figure 3).
3.4. SIRT1 Activation Restored SOD2 Activity in RTECs following CLP
Since several reports claim that SOD2 is one of the deacetylated targets of SIRT1/3, we determined protein expression, acetylation level, and activity of SOD2 in RTECs following CLP. As expected, RSV treatment slightly restored the SOD2 protein content and remarkably decreased the acetylated SOD2 level (Ac-lys), leading to elevated SOD2 activity (Figure 4).
3.5. SIRT1 Activation Ameliorated Oxidative Stress in RTECs following CLP
Since SOD2 activity was significantly restored by SIRT1 activation and SOD2 is a key antioxidative enzyme, we tested GSH content, GSH/GSSG ratio, and CAT activity in RTECs. The GSH content, GSH/GSSG ratio, and CAT activity were considerably decreased after CLP in the vehicle group and were partially restored by SIRT1 activation in the RSV treatment group; however, after Ex527 was added, the beneficial effect of RSV was greatly blocked and was almost equivalent to that in the vehicle group (Figure 5).
3.6. SIRT1 Activation Attenuated MD in RTECs following CLP
Due to the positive effect of SIRT1 activation on SOD2, an antioxidative stress enzyme located in the mitochondria, we also tested the mitochondrial morphology and function in RTECs. An elliptical shape with well-developed cristae and electron-dense matrices was noted in the control group. Severe MD was found after CLP treatment (vehicle group), evidencing by irregularly shaped, swollen, and disrupted mitochondria with poorly defined cristae and electron-lucent matrices. Surprisingly, these changes were restored by treatment with RSV. Moreover, RSV treatment restored the mitochondrial transmembrane potential (JC-1 aggregates/monomer), enhanced ATP content, and inhibited the opening of mPTP. However, these beneficial effects of RSV were considerably blocked by Ex527 addition (Figure 6).
3.7. SIRT1 Activation Inhibited Apoptosis in RTECs
We subsequently tested the effect of SIRT1 activation on apoptosis in RTECs; a mitochondria-related apoptosis index (cytochrome C) and a general apoptosis index (TUNEL) were selected. The mitochondrial cytochrome C (mito-cyt C) was decreased and the cytoplasmic cytochrome C (cyto-cyt C) was increased after CLP treatment. Moreover, the number of TUNEL-positive cells was significantly increased. As expected, RSV administration reduced the cyto-cyt C content and decreased the number of TUNEL-positive cells. However, the beneficial effects of RSV were reversed considerably by Ex527 addition (Figure 7).
3.8. SIRT1 Activation Protected Renal Function and Prolonged Survival Time in Septic Rat
Finally, we tested the effect of SIRT1 activation on renal function and survival time. Both the creatinine and urea nitrogen were elevated in septic rat, accompanied by shortened survival time. SIRT1 activation by RSV considerably reduced the level of creatinine and blood urea nitrogen. Importantly, RSV administration greatly prolonged the survival of sepsis animal. However, the beneficial effect of RSV on renal function and survival time were partially abrogated by Ex527 (Supplementary Figure ).
Our results showed that SIRT1/3 activity was reduced in the RTECs of septic rat and was accompanied by higher acetylated SOD2 levels, swollen mitochondria, and increased cell apoptosis. Moreover, SIRT1 activation by RSV could partially restore SIRT3 activity and attenuate MD, leading to improved mitochondrial function and reduced apoptosis. Furthermore, all the beneficial effects of SIRT1 activation were considerably reduced by a selective inhibitor. To the best of our knowledge, this is a first report describing a role for SIRT1/3 in the pathogenesis of sepsis-associated AKI.
SIRTs, first discovered in yeast as NAD+-dependent epigenetic and metabolic regulators, have comparable activities in human physiology and disease . There is increasing evidence that SIRT1 mediates protein posttranslational modification related to aging and ischemic disease [19–21]. In our previous studies, we showed that SIRT1 activation could ameliorate MD in hepatocytes , vascular smooth muscle cells , small intestine epithelial cells, and RTECs  in a severe hemorrhagic shock rat model, consistent with reports of the beneficial effects of SIRT1 in ischemic conditions. However, the role of SIRT1 in sepsis is rarely studied and its exact mechanism is yet to be determined. Recently, a study showed that SIRT1 knockdown mice exhibited aggravated inflammatory signaling such as NF-kappa B in lung tissue of CLP mice . Furthermore, pharmacological SIRT1 activation decreased mortality in experimental sepsis . Importantly, RSV was found to effectively inhibit inflammatory responses by acting as a SIRT1 activator . Some studies have shown that HMGB1 is a main downstream deacetylated target of SIRT1  and SIRT1 activation inhibited HMGB1 secretion . In contrast, some reports have claimed that SIRT1 inhibition, but not activation, could be a novel way to treat sepsis in its hypoinflammatory phase . Liu et al. used TLR4-stimulated THP1 human promonocytes to mimic the adaptation stages of sepsis. They found that nuclear SIRT1 guides RELB to differentially induce SIRT3 expression and increase mitochondrial biogenesis. Based on their results, they claimed that SIRT1 inhibition repressed bioenergetics during sepsis adaptation and finally improved survival time . This seeming discrepancy may suggest that the treatment of sepsis should differ based on the phase of sepsis. In this study, we demonstrated that SIRT1 protein levels and activity in kidney tissue progressively declined in the early phase (−8 h) of sepsis. Even though SIRT1 protein levels partially increased after 8 h, the activity was barely restored at 24 h. The compensatory response of the organism may account for this phenomenon. This result also suggests the importance of timing for therapy. In this study, we used a potential SIRT1 activator, resveratrol, for treatment of sepsis. We found that SIRT1 activation effectively protected mitochondrial function in RTECs and ameliorated renal function (Supplementary Figure ). However, when a special inhibitor of SIRT1, Ex527, was added, the beneficial effect of RSV was greatly abrogated. These results indicate that SIRT1 is a promising target for pharmacological intervention in septic AKI.
In terms of mitochondrial function, SIRT3 is another known deacetylating enzyme. A growing body of evidence has confirmed that SIRT3 defends against oxidative stress in multiple diseases including ischemia and neurodegenerative disease. Genetic inference or genetic knockout of SIRT3 accelerates diet-induced obesity, type 2 diabetes, and nonalcoholic fatty liver disease . SIRT3 activation can deacetylate its downstream target SOD2 (also termed manganese superoxide dismutase, Mn-SOD), leading to a reduction in oxygen free radicals in the mitochondria and other subcellular organelles [12, 13]. Interestingly, the relationship between the functions of nuclear SIRT1 and mitochondrial SIRT3 is coordinated during the hypoinflammatory phase of sepsis in THP1 human promonocytes . Liu et al. found that SIRT1, RELB, and SIRT3 act in sequence to modify mitochondrial bioenergetics. They proved that the suppression of SIRT1/3 protein expression could improve the survival of septic mice . However, the relative role of each protein in influencing sepsis outcomes and how their programming is coordinated must still be determined. In this study, we did not directly test the effects of SIRT3; instead, we activated or deactivated SIRT1 using chemical agents and found that SIRT3 activity is considerably reduced in the RTECs of septic rat. Moreover, SIRT1 activation by RSV partially restored SIRT3 activity, indicating that SIRT1 might be an upstream regulator of SIRT3 or might provide cooperative protection, decreasing acetylated SOD2 and restoring SIRT3 activity. The protein content of the antioxidative enzyme GSH and activity of CAT were reduced. However, the activation effect of SIRT1 on SIRT3 disappeared when a selective inhibitor targeted at SIRT3, 3-TYP, was added.
Some reports have confirmed that the dysfunction of the renal peritubular microenvironment leads to sepsis-induced AKI . The swelling of RTECs owing to LPS stimulation was found to cause proximal tubule obstruction and reduce tubular flow rate . These reports indicate the vital role of RTECs in kidney function. Further, in our previous report, we demonstrated that MD existed in RTECs in the septic rat . In agreement with the aforementioned studies, we confirmed that RTECs are among the more susceptible cells in kidney tissue. Besides RTECs, we also observed SIRT1 activity in glomerular epithelial cells (Supplementary Figure ). These results collectively suggest that SIRT1 plays a considerable role in the pathogenesis of septic AKI.
Our study has some potential limitations. Firstly, sepsis is a dynamic disease. It changes from the hyperinflammatory to hypoinflammatory phase. In this study, we only assessed the early (hyperinflammatory) phase of sepsis; further studies regarding therapeutic options during the hypoinflammatory phase are needed. However, this study provides a prevention strategy for sepsis AKI treatment, which partially elucidates the SIRT1-SIRT3 axis in the pathogenesis of sepsis. Secondly, we applied a chemical activator and a selective inhibitor against SIRT1; more intensive methods such as genetic inference or genetic knockout may provide stronger evidence. Thirdly, we only explored the effects of SIRT1 in RTECs; reduction of SIRT1 activity also occurs in other types of kidney cells and will certainly be a worthwhile direction for future studies.
This study outlines an important role for SIRT1 in the reversal of AKI following sepsis. In addition, our findings suggest that RSV treatment exerts a profound protective effect against renal injury caused by sepsis. This protection appears to be largely due to the ability to activate SIRT1 and SIRT3, augment SOD2-mediated antioxidative ability, and mitochondrial protection.
|AKI:||Acute kidney injury|
|RTEC:||Renal tubular epithelial cell|
|CLP:||Cecal ligation and puncture|
|ac-SOD2:||Acetylated superoxide dismutase 2|
|GSH:||Reduced form of glutathione|
|GSSG:||Oxidized form of glutathione|
|TUNEL:||Terminal deoxynucleotidyl transferase dUTP nick-end labeling|
|WST:||Water-soluble tetrazolium salt|
|GAPDH:||Glyceraldehyde 3-phosphate dehydrogenase|
|:||Mitochondrial membrane potential|
|mPTP:||Mitochondrial permeability transition pore|
The authors declare that there is no conflict of interests regarding the publication of this paper.
Ke-seng Zhao and Zhenhua Zeng prepared the concept and designed the research; Siqi Xu, Youguang Gao, Qin Zhang, Siwei Wei, and Xingui Dai performed the experiments; Zhenhua Zeng, Zhongqing Chen, and Ke-seng Zhao analyzed data; Xiqi Xu and Youguang Gao prepared the figures; Siqi Xu, Qin Zhang, Zhenhua Zeng, and Ke-seng Zhao interpreted the results of experiments; Siqi Xu and Youguang Gao drafted the paper; Zhenhua Zeng and Ke-seng Zhao edited and revised the paper. All the authors read and approved the final version of the paper. Siqi Xu and Youguang Gao contributed equally to this paper.
This work was supported by the Natural Science Foundation of Fujian Province, China [Grant no. 2016J01451] and the President Foundation of Nanfang Hospital, Southern Medical University, Guangzhou, China [Grant nos. 2015C005 and 2015Z001].
Supplemental figure 1. Expression and activity of SIRT1 protein in glomerular epithelial cells after CLP. (a). Representative western blot of SIRT1 proteins (upper panel) and densitometric analyses (lower panel); (b) SIRT1 activity was determined using a SIRT1 Assay kit and normalized to that of the control group. Values are presented as the mean ± SEM. 11p < 0.01 vs. the control group; 22p < 0.01 vs. the vehicle group; 33p < 0.01 vs. the RSV group; 44p < 0.01 vs. the RSV+Ex527 group. n = 6. SIRT1, sirtuin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RSV, resveratrol; SRT, SRT1720.
- M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (Sepsis-3),” The Journal of the American Medical Association, vol. 315, no. 8, pp. 801–810, 2016.
- C. M. Torio and R. M. Andrews, National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011, Statistical Brief #160, 2006.
- J.-L. Vincent, J. C. Marshall, S. A. Ñamendys-Silva et al., “Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit,” The Lancet Respiratory Medicine, vol. 2, no. 5, pp. 380–386, 2014.
- C. Fleischmann, A. Scherag, N. K. Adhikari et al., “Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations,” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 3, pp. 259–272, 2016.
- X. Dai, Z. Zeng, C. Fu, S. Zhang, Y. Cai, and Z. Chen, “Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury,” Critical Care, vol. 19, article 223, 2015.
- M. Tran, D. Tam, A. Bardia et al., “PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice,” The Journal of Clinical Investigation, vol. 121, no. 10, pp. 4003–4014, 2011.
- Y. Gao, Z. Zeng, T. Li et al., “Polydatin inhibits mitochondrial dysfunction in the renal tubular epithelial cells of a rat model of sepsis-induced acute kidney injury,” Anesthesia and Analgesia, vol. 121, no. 5, pp. 1251–1260, 2015.
- R. Nogueiras, K. M. Habegger, N. Chaudhary et al., “Sirtuin 1 and sirtuin 3: physiological modulators of metabolism,” Physiological Reviews, vol. 92, no. 3, pp. 1479–1514, 2012.
- V. T. Vachharajani, T. Liu, X. Wang, J. J. Hoth, B. K. Yoza, and C. E. McCall, “Sirtuins link inflammation and metabolism,” Journal of Immunology Research, vol. 2016, Article ID 8167273, 10 pages, 2016.
- R. Gao, Z. Ma, Y. Hu, J. Chen, S. Shetty, and J. Fu, “Sirt1 restrains lung inflammasome activation in a murine model of sepsis,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 308, no. 8, pp. L847–L853, 2015.
- S. Opal, J. L. Ellis, V. Suri et al., “Harmacological Sirt1 activation improves mortality and markedly alters transcriptional profiles that accompany experimental sepsis,” Shock, vol. 45, no. 4, pp. 411–418, 2016.
- H. Pi, S. Xu, R. J. Reiter et al., “SIRT3-SOD2-mROS-dependent autophagy in cadmium-induced hepatotoxicity and salvage by melatonin,” Autophagy, vol. 11, no. 7, pp. 1037–1051, 2015.
- X. Qiu, K. Brown, M. D. Hirschey, E. Verdin, and D. Chen, “Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation,” Cell Metabolism, vol. 12, no. 6, pp. 662–667, 2010.
- P. Li, X. Meng, H. Bian, N. Burns, K.-S. Zhao, and R. Song, “Activation of sirtuin 1/3 improves vascular hyporeactivity in severe hemorrhagic shock by alleviation of mitochondrial damage,” Oncotarget, vol. 6, no. 35, pp. 36998–37011, 2015.
- Z. Zeng, Y. Yang, X. Dai et al., “Polydatin ameliorates injury to the small intestine induced by hemorrhagic shock via SIRT3 activation-mediated mitochondrial protection,” Expert Opinion on Therapeutic Targets, vol. 20, no. 6, pp. 645–652, 2016.
- D. H. Shin, Y.-J. Choi, and J.-W. Park, “SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin,” Cancer Research, vol. 74, no. 1, pp. 298–308, 2014.
- Z. Zeng, Z. Chen, S. Xu et al., “Polydatin protecting kidneys against hemorrhagic shock-induced mitochondrial dysfunction via SIRT1 activation and p53 deacetylation,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1737185, 15 pages, 2016.
- Z. Zeng, Z. Chen, S. Xu, R. Song, H. Yang, and K.-S. Zhao, “Polydatin alleviates small intestine injury during Hemorrhagic shock as a SIRT1 activator,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 965961, 12 pages, 2015.
- R. H. Houtkooper, E. Pirinen, and J. Auwerx, “Sirtuins as regulators of metabolism and healthspan,” Nature Reviews Molecular Cell Biology, vol. 13, no. 4, pp. 225–238, 2012.
- M.-K. Han, E.-K. Song, Y. Guo, X. Ou, C. Mantel, and H. E. Broxmeyer, “SIRT1 regulates apoptosis and nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization,” Cell Stem Cell, vol. 2, no. 3, pp. 241–251, 2008.
- B. Jian, S. Yang, I. H. Chaudry, and R. Raju, “Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1,” Molecular Medicine, vol. 18, no. 2, pp. 209–214, 2012.
- P. Li, X. Wang, M. Zhao, R. Song, and K.-S. Zhao, “Polydatin protects hepatocytes against mitochondrial injury in acute severe hemorrhagic shock via SIRT1-SOD2 pathway,” Expert Opinion on Therapeutic Targets, vol. 19, no. 7, pp. 997–1010, 2015.
- X. Wang, R. Song, H. N. Bian, U. T. Brunk, M. Zhao, and K.-S. Zhao, “Polydatin, a natural polyphenol, protects arterial smooth muscle cells against mitochondrial dysfunction and lysosomal destabilization following hemorrhagic shock,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 302, no. 7, pp. R805–R814, 2012.
- S. M. Opal, J. L. Ellis, V. Suri et al., “Pharmacological SIRT1 activation improves mortality and markedly alters transcriptional profiles that accompany experimental sepsis,” Shock, vol. 45, no. 4, pp. 411–418, 2016.
- T. Li, J. Zhang, J. Feng et al., “Resveratrol reduces acute lung injury in a LPS-induced sepsis mouse model via activation of Sirt1,” Molecular Medicine Reports, vol. 7, no. 6, pp. 1889–1895, 2013.
- J. S. Hwang, H. S. Choi, S. A. Ham et al., “Deacetylation-mediated interaction of SIRT1-HMGB1 improves survival in a mouse model of endotoxemia,” Scientific Reports, vol. 5, Article ID 15971, 2015.
- T. D. Walko III, V. Di Caro, J. Piganelli, T. R. Billiar, R. S. Clark, and R. K. Aneja, “Poly(ADP-ribose) polymerase 1-sirtuin 1 functional interplay regulates LPS-mediated high mobility group box 1 secretion,” Molecular Medicine, vol. 20, pp. 612–624, 2014.
- V. T. Vachharajani, T. Liu, C. M. Brown et al., “SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome,” Journal of Leukocyte Biology, vol. 96, no. 5, pp. 785–796, 2014.
- T. F. Liu, V. Vachharajani, P. Millet, M. S. Bharadwaj, A. J. Molina, and C. E. McCall, “Sequential actions of SIRT1-RELB-SIRT3 coordinate nuclear-mitochondrial communication during immunometabolic adaptation to acute inflammation and sepsis,” The Journal of Biological Chemistry, vol. 290, no. 1, pp. 396–408, 2015.
- P. R. Mayeux and L. A. MacMillan-Crow, “Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury,” Pharmacology and Therapeutics, vol. 134, no. 2, pp. 139–155, 2012.
- D. Nakano, K. Doi, H. Kitamura et al., “Reduction of tubular flow rate as a mechanism of oliguria in the early phase of endotoxemia revealed by intravital imaging,” Journal of the American Society of Nephrology, vol. 26, no. 12, pp. 3035–3044, 2015.
Copyright © 2016 Siqi Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.